Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix's wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit .SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present a corporate update at the Piper Sandler 36th Annual Healthcare Conference, at 2:30 p.m. ET on Tuesday, December 3, 2024, in New York City.
舊金山，2024年11月25日（環球新聞）—— nurix therapeutics公司（納斯達克：NRIX）是一家臨床階段的生物製藥公司，開發針對癌症和炎症疾病患者的靶向蛋白調節藥物。今天宣佈，nurix的總裁兼首席執行官亞瑟·t·桑茲萬.D.，博士，將於2024年12月3日（星期二）東部時間下午2:30在紐約市的派傑投資第36屆年度醫療保健會議上進行企業更新。
The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. The archived webcast will be available for 30 days after the event.
該活動將進行現場直播，您可以通過nurix網站投資者部分的活動和演示鏈接訪問。活動結束後，存檔的網絡廣播將在30天內提供。
About Nurix Therapeutics, Inc.
關於nurix therapeutics，Inc。
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix's wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit .
nurix therapeutics是一家臨床階段的生物製藥公司，專注於基於調節細胞蛋白水平的創新小分子和抗體療法的發現、開發和商業化，作爲對癌症、炎症性疾病和其他挑戰性疾病的新型治療方法。憑藉E3連接酶領域的廣泛專業知識，結合專有的DNA編碼文庫，Nurix構建了DELigase集成發現平台，用於識別和推進以E3連接酶爲靶點的新藥候選物，這是一個可以在細胞內調節蛋白質的廣泛酶類。Nurix的藥物發現方法是利用或抑制泛素-蛋白酶體系統中E3連接酶的自然功能，以有選擇地降低或增加細胞蛋白水平。Nurix完全擁有的臨床管線包括以布魯頓氨基酸激酶爲靶點的靶向蛋白降解劑，一種b細胞信號蛋白，以及卡西塔斯b-細胞系淋巴瘤原癌基因b的抑制劑，它是一種調節多種免疫細胞類型（包括t細胞和Nk細胞）激活的E3連接酶。Nurix總部位於加利福尼亞州舊金山。有關更多信息，請訪問。
Contacts:
聯繫人：
Investors
投資者
Jason Kantor, Ph.D.
Nurix Therapeutics
ir@nurixtx.com
Jason Kantor博士。
nurix therapeutics
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
伊麗莎白·沃爾夫博士。
Wheelhouse 生命科學顧問公司
lwolffe@wheelhouselsa.com
Media
媒體
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse 生命科學顧問公司
areynolds@wheelhouselsa.com
譯文內容由第三人軟體翻譯。
